Anti-IL-6 vaccine(Peptinov)(Anti-IL-6 vaccine(Peptinov)) - 药物靶点：IL-6_在研适应症：膝关节炎_专利_临床

概要

基本信息

药物类型

合成肽疫苗、治疗性疫苗

别名

Anti-IL-6 vaccine

靶点

IL-6

作用机制

IL-6调节剂(白细胞介素-6调节剂)

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病

在研适应症

膝关节炎

非在研适应症-

原研机构

Peptinov SAS

在研机构

Peptinov SAS

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Anti-IL-6 vaccine(Peptinov) 相关的临床试验

NCT06605963 / Not yet recruiting临床2期

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of PPV-06 Active Immunotherapy in Patients With Inflammatory Knee Osteoarthritis (KOA)

PPV-06 targets interleukin-6, a key molecule implicated in many inflammatory diseases such osteoarthritis. PPV-06 is used to induce the production of antibodies directed against IL-6. The antibodies produced will neutralize the interleukine-6 involved in the body's inflammatory process.
The goal of this clinical trial is to test the safety and efficacy of PPV-06 in participants with Knee Osteoarthritis. The main questions are to evaluate if PPV-06 can reduce pain and improve functioning in participants with knee osteoarthritis, and to evaluate if ¨PPV-06 is safe when administered to participants.
Participants will be administered with 6 subcutaneous injections of either PPV-06 or placebo, over a two-year period.

开始日期2024-12-01

申办/合作机构

Peptinov SAS

NCT04447898 / Completed临床1期

A Randomized, Double-blind, Placebo-controlled, Dose Escalation Phase I Study Assessing the Safety and Immune Response of PPV-06 Vaccine in Patient With Inflammatory Knee Osteoarthritis (KOA)

PPV-06 immunotherapy targets interleukin-6 (IL-6), a key molecule of the immune system whose overproduction is implicated in many inflammatory and autoimmune diseases such as rheumatoid arthritis and osteoarthritis. The benefit of vaccination with PPV-06 is to induce, in response to immunizations, the production of antibodies directed against IL-6. The antibodies produced will neutralize the biological activity of IL-6 involved in the body's inflammatory process.
The primary objective is to evaluate the safety/tolerability of vaccination with PPV-06.

开始日期2021-02-18

申办/合作机构

Peptinov SAS

100 项与 Anti-IL-6 vaccine(Peptinov) 相关的临床结果

登录后查看更多信息

100 项与 Anti-IL-6 vaccine(Peptinov) 相关的转化医学

登录后查看更多信息

100 项与 Anti-IL-6 vaccine(Peptinov) 相关的专利（医药）

登录后查看更多信息

12

项与 Anti-IL-6 vaccine(Peptinov) 相关的文献（医药）

2023-01-01·Tanaffos

Cytokine Release Syndrome (CRS) in Severe COVID-19 Patients: Two Controversial and Interesting Case Reports and Literature Review.

作者: Dmitrovic, Radmila ; Esquinas, Antonio M ; Lazovic, Biljana ; Simonovic, Isidora

BackgroundCytokine release syndrome (CRS) represents a potentially life-threatening and systematic inflammatory response where it is noted an increase of secretion of proinflammatory cytokines from lymphocytes, myeloid cells like macrophages, dendritic cells, and monocytes. This syndrome is characteristic of some conditions such as viral infections, administration of antibody-based therapy, auto immune disease, and immunotherapy, especially in severe COVID-19 patients.Case reportsWe presented two cases of COVID-19 patients in which the clinical picture significantly deteriorated during hospitalization, where the value of CRP, ferritin, LDH, and IL-6 dramatically increased, especially values of IL-6 were recorded over 2000. We treated them with third-generation cephalosporins, carbapenems, glycopeptides, metronidazole, anti-IL-6 inhibitor, low molecular weight heparin (LMWH), glucocorticoids, immunoglobulins (IVIG), and vitamins. Both patients were successfully treated and were discharged from the hospital with a recommendation for oral anticoagulant therapy.ConclusionCRS is a complex syndrome. In the future, it is necessary to educate doctors about this syndrome, as well as to develop drugs whose goal would be to reduce the inflammatory response in already developed diseases.

2022-10-01·The Veterinary Journal

Targeting eosinophils by active vaccination against interleukin-5 reduces basophil counts in horses with insect bite hypersensitivity in the 2nd year of vaccination

Article

作者: Birkmann, Katharina ; Fettelschoss, Victoria ; Schoster, Angelika ; Fettelschoss-Gabriel, Antonia ; Rhiner, Tanya

Previously, virus-like particle (VLP)-based self-vaccinations targeting interleukin (IL)-5 or IL-31 have been suggested to treat equine insect bite hypersensitivity (IBH), a seasonal recurrent allergic dermatitis in horses. The IL-5-targeting equine vaccine significantly reduced blood eosinophil counts in horses, similar to human monoclonal antibodies targeting IL-5 or the IL-5 receptor alpha (IL-5Rα). Previous studies in humans have also reported an additional effect on reduction of basophil counts. The aim of the present study was to evaluate whether an equine anti-IL-5 vaccine affected blood basophil counts. Horses with IBH were followed in a 3-year trial consisting of a placebo administered in the 1st year, followed by vaccination using an equine (e)IL-5-VLP vaccine in the 2nd and 3rd years. There was a strong reduction in circulating eosinophil counts after vaccination against IL-5. Additionally, there were reduced basophil counts, but only in the 3rd year of the study, suggesting a bystander effect of the anti-IL-5 vaccine on basophil counts.

2014-02-01·Pharmacology & Therapeutics1区 · 医学

Targeting interleukin-6 in inflammatory autoimmune diseases and cancers

1区 · 医学

Review

作者: Fung, Michael ; Huang, Jiaqi ; Faggioni, Raffaella ; Zhong, Haihong ; Yao, Yihong ; Shen, Nan ; Yao, Xin

Interleukin-6 (IL-6) is a pleiotropic cytokine with significant functions in the regulation of the immune system. As a potent pro-inflammatory cytokine, IL-6 plays a pivotal role in host defense against pathogens and acute stress. However, increased or deregulated expression of IL-6 significantly contributes to the pathogenesis of various human diseases. Numerous preclinical and clinical studies have revealed the pathological roles of the IL-6 pathway in inflammation, autoimmunity, and cancer. Based on the rich body of studies on biological activities of IL-6 and its pathological roles, therapeutic strategies targeting the IL-6 pathway are in development for cancers, inflammatory and autoimmune diseases. Several anti-IL-6/IL-6 receptor monoclonal antibodies developed for targeted therapy have demonstrated promising results in both preclinical studies and clinical trials. Tocilizumab, an anti-IL-6 receptor antibody, is effective in the treatment of various autoimmune and inflammatory conditions notably rheumatoid arthritis. It is the only IL-6 pathway targeting agent approved by the regulatory agencies for clinical use. Siltuximab, an anti-IL-6 antibody, has been shown to have potential benefits treating various human cancers either as a single agent or in combination with other chemotherapy drugs. Several other anti-IL-6-based therapies are also under clinical development for various diseases. IL-6 antagonism has been shown to be a potential therapy for these disorders refractory to conventional drugs. New strategies, such as combination of IL-6 blockade with inhibition of other signaling pathways, may further improve IL-6-targeted immunotherapy of human diseases.

100 项与 Anti-IL-6 vaccine(Peptinov) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膝关节炎	临床2期	法国	Peptinov SAS	2024-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04447898 (EULAR2024) 人工标引	临床1期	膝关节炎	24	PPV-06 low dose	(憲襯衊醖蓋廠蓋繭選獵) = 廠餘憲衊觸獵糧製顧顧築選遞簾齋壓衊網積網 (繭簾繭夢觸鹹鏇鹽壓鹹, 0 ~ 33.6) 更多	积极	2024-06-12
				PPV-06 high dose	(憲襯衊醖蓋廠蓋繭選獵) = 網醖鹽憲築網積齋襯積築選遞簾齋壓衊網積網 (繭簾繭夢觸鹹鏇鹽壓鹹, 0 ~ 33.6) 更多